BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Frequently asked questions
What sector does BioLine RX Ltd (BLRX) operate in?
BioLine RX Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is BioLine RX Ltd (BLRX) current stock price?
As of the latest data, BioLine RX Ltd stock price is ₪0.02, with a previous close of ₪0.02.
What is BioLine RX Ltd (BLRX) current market capitalization?
BioLine RX Ltd market cap is approximately 39.16 million.
What is BioLine RX Ltd (BLRX) EBITDA?
BioLine RX Ltd EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -7.07 million.
Does BioLine RX Ltd (BLRX) pay dividends?
No. BioLine RX Ltd does not pay a dividend.
What is BioLine RX Ltd (BLRX) beta (volatility) score?
BioLine RX Ltd has a beta of 0.711, indicating lower volatility than the overall market.
